APPLIED VASCULAR ENGINEERING BEGINS CLINICALS FOR CORONARY MICRO STENT; STUDY OF UP TO 700 PATIENTS WILL COMPARE DEVICE TO J&J'S PALMAZ-SCHATZ
This article was originally published in The Gray Sheet
Executive Summary
Patient enrollment for an investigational device exemption study of Applied Vascular Engineering, Inc.'s coronary Micro Stent began the week of Nov. 6. On Nov. 3, AVE received an IDE for the prospective, randomized study, which will compare the Micro Stent to Johnson & Johnson's Palmaz-Schatz device. Patient enrollment is anticipated to continue for six to 12 months, and a premarket approval application for the device could be submitted in 18-24 months, AVE predicts.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.